Clinical Trial Update: Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating chemotherapy for newly diagnosed very low-risk and low-risk fusion-negative rhabdomyosarcoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Rhabdomyosarcoma
• Embryonal Rhabdomyosarcoma
• Spindle Cell Sclerosing Rhabdomyosarcoma

Snippet

Sponsor: Children's Oncology Group | Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma | Phase 3 | Status: RECRUITING